PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer

Yingzi Zhang, Yan Yang, Yiran Chen, Lin Wu, Xiangliu Chen, Jin Liu, Yingying Huang, Haiyong Wang, Lisong TengFrontiers in Immunology 2022 · DOI

Abstract

Gastric cancer (GC) remains a leading cause of cancer-related mortality worldwide. While traditional treatments offer limited success in advanced stages, the emergence of immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis has significantly improved patient prognosis. This review explores the complex endogenous and exogenous regulatory mechanisms of PD-L1 in GC, its role in promoting malignant phenotypes, and the current landscape of clinical trials. Understanding these molecular characteristics is essential for maximizing the clinical benefits of immunotherapy through personalized treatment strategies.

Introduction

Gastric cancer is frequently diagnosed at advanced stages, where the efficacy of surgery and chemotherapy is constrained. The introduction of ICIs has revolutionized the field, yet clinical responses remain highly variable. To optimize these therapies, it is critical to understand the underlying mechanisms that drive PD-L1 expression and how it facilitates both immune evasion and tumor progression.

Regulatory Mechanisms of PD-L1

Intracellular Regulation

PD-L1 expression is controlled at multiple levels within the gastric cancer cell. At the transcriptional level, pathways such as EGFR, mTOR, and HIF-1α (under hypoxic conditions) trigger the production of PD-L1 mRNA. Post-translational modifications also play a vital role; for instance, the de-ubiquitinating enzyme USP7 stabilizes the PD-L1 protein, preventing its degradation and ensuring its presence on the cell surface to inhibit T-cell activity.

Figure 1: Intracellular signaling pathways and post-translational mechanisms, including USP7-mediated stabilization, that regulate PD-L1 expression in gastric cancer cells.

The Tumor Microenvironment (TME)

Beyond internal signaling, the "neighborhood" surrounding the tumor significantly influences PD-L1 levels. Gastric cancer cells recruit various immune cells, including neutrophils, macrophages, and mast cells, into the TME. These cells secrete cytokines like GM-CSF and TNF-α, which activate pathways such as JAK/STAT3 and NF-κB within the tumor cells. This creates a reinforcing feedback loop that upregulates PD-L1, further suppressing the local immune response.

Figure 2: The interaction between gastric cancer cells and the immune microenvironment, showing how recruited neutrophils and mast cells secrete cytokines to drive PD-L1 upregulation.

Clinical Synthesis and Immunotherapy

Key Clinical Trials

Major Phase I-III trials have established the role of ICIs in GC treatment. Notably, the CheckMate-649 trial demonstrated that combining Nivolumab with standard chemotherapy significantly improved overall survival (OS) and progression-free survival (PFS) compared to chemotherapy alone. The Combined Positive Score (CPS) has emerged as a vital biomarker, with patients scoring CPS ≥ 5 or ≥ 10 deriving the greatest benefit from these therapies.

Molecular Subtyping

Personalized medicine in GC relies heavily on molecular stratification. Patients with EBV-positive (EBV+) or Microsatellite Instability-High (MSI-H) status typically show the most robust responses to anti-PD-1/PD-L1 agents. Conversely, HER2-positive patients often require a combination of Trastuzumab and ICIs to achieve optimal results.

Biological Functions Beyond Immune Evasion

PD-L1 is more than a passive shield; it actively promotes malignancy. High PD-L1 expression is linked to the Epithelial-Mesenchymal Transition (EMT), which enhances the metastatic potential of GC cells. Furthermore, it increases cancer stem cell characteristics, contributing to drug resistance and tumor recurrence.

Future Directions and Limitations

Despite progress, challenges remain:

  • Hyper-Progressive Disease (HPD): A subset of patients experiences accelerated tumor growth following ICI treatment, the mechanisms of which are still being investigated.
  • "Cold" Tumors: Many GCs lack sufficient T-cell infiltration. Future strategies aim to "heat up" these tumors using radiotherapy or novel nanoparticles to improve ICI susceptibility.
  • Microbiome: Emerging evidence suggests the gut-tumor axis may modulate immunotherapy responses, offering a new frontier for research.

In conclusion, while PD-1/PD-L1 inhibitors have transformed the management of gastric cancer, a deeper understanding of the regulatory landscape and the development of precise biomarkers are necessary to overcome resistance and improve long-term survival.

Summary updated

Abstract

Gastric cancer (GC) is one of the main causes of cancer incidence rate and mortality worldwide. As the main breakthrough direction, the application of immune checkpoint inhibitors makes patients with GC have better prognosis, where PD-L1/PD-1 inhibitors in immunotherapy have good anti-tumor immune efficacy. Further understanding of the regulatory mechanism of PD-L1 in GC may bring substantial progress to the immunotherapy. In this review, we provide information on the endogenous and exogenous regulatory mechanisms of PD-L1 and its biological functions combined with current clinical trials of PD-L1/PD-1 inhibitors in GC. The malignant biological phenotypes caused by PD-L1 and the corresponding clinical combined treatment scheme have been reported. Identifying the biomarkers of the potential efficacy of immunotherapy and specifying the clinical immunotherapy scheme in combination with molecular characteristics of patients may maximize clinical benefits and better prognosis.
BibTeX
@inproceedings{zhang2022pd,
  author = {Yingzi Zhang and Yan Yang and Yiran Chen and Lin Wu and Xiangliu Chen and Jin Liu and Yingying Huang and Haiyong Wang and Lisong Teng},
  title = {{PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer}},
  booktitle = {Frontiers in Immunology},
  year = {2022},
  doi = {10.3389/fimmu.2022.1060497},
}
Figure